Back to Clinical Trials Overview

Your search for "Liver Disorders" returned 21 results:


Genomics of Primary Biliary Cirrhosis
Principal Investigator(s): Joseph Odin

Characterization of Acute HCV Infection
Principal Investigator(s): Fierer, Daniel S

A Phase 3 Multicenter Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects with Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection
Principal Investigator(s): Meena Bansal

A randomized double-blind controlled evaluation of tenofovir DF versus adefovir dipivoxil for the treatment of presumed pre-core mutant chronic hepatitis B
Principal Investigator(s): Odin, Joseph A

A Phase 2b Dose-Ranging Randomized Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624 a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) in Subjects with Advanced Liver Fibrosis but not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis
Principal Investigator(s): Charissa Chang

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

Longitudinal Study of Mitochondrial Hepatopathies (MITOHEP)
Principal Investigator(s): Suchy, Frederick J.

Biliary Atresia Study in Infants and Children (BASIC)
Principal Investigator(s): Suchy, Frederick J.

A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4 and GT6 Infection with Inherited Blood Disorders with and without HIV Co-Infection
Principal Investigator(s): Ponni Perumalswami

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis (CENTAUR)
Principal Investigator(s): Meena Bansal

Simeprevir (SMV)+Sofosbuvir (SOF) with or without Ribavirin (RBV) for Interferon-intolerant or ineligible (IFN-II) Patients with Chronic Hepatitis C (CHC)
Principal Investigator(s): Ritu Agarwal

HCC BRIDGE study: Bridge to better outcomes in HCC
Principal Investigator(s): Schwartz, Myron MD

A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3
Principal Investigator(s): Ponni Perumalswami

Cholestatic Liver Disease Consortium- Longitudinal Studies of Genetic Causes of Intrahepatic Cholestasis(LOGIC)
Principal Investigator(s): Suchy, Frederick J.

Prospective Database of Infants with Cholestasis (PROBE)
Principal Investigator(s): Suchy, Frederick J.

A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Joseph Odin

Phase 3 Multicenter Randomized Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks with Sofosbuvir and Ribavirin for 12 Weeks in Subjects with Chronic Genotype 2 HCV Infection
Principal Investigator(s): Ritu Agarwal

A Long Term Follow-up Registry Study for Subjects Who Achieve A Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

Corticosteroid Therapy in Infants w/ Bilary Atresia (START Trial)
Principal Investigator(s): Suchy, Frederick J.

An Open-Label Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
Principal Investigator(s): Douglas Dieterich

A Phase 2 Randomized Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the treatment of subjects with chronic hepatitis B and who are currently not on treatment
Principal Investigator(s): Jennifer Leong